GH RESEARCH PLC DL-025 - Asset Resilience Ratio
GH RESEARCH PLC DL-025 (1KA) has an Asset Resilience Ratio of 4.73% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of GH RESEARCH PLC DL-025 for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how GH RESEARCH PLC DL-025's Asset Resilience Ratio has changed over time. See 1KA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down GH RESEARCH PLC DL-025's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GH RESEARCH PLC DL-025 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €17.60 Million | 4.73% |
| Total Liquid Assets | €17.60 Million | 4.73% |
Asset Resilience Insights
- Limited Liquidity: GH RESEARCH PLC DL-025 maintains only 4.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GH RESEARCH PLC DL-025 Industry Peers by Asset Resilience Ratio
Compare GH RESEARCH PLC DL-025's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
Annual Asset Resilience Ratio for GH RESEARCH PLC DL-025 (2022–2025)
The table below shows the annual Asset Resilience Ratio data for GH RESEARCH PLC DL-025.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.95% | €34.46 Million ≈ $40.28 Million |
€288.23 Million ≈ $336.97 Million |
-13.82pp |
| 2024-12-31 | 25.78% | €48.53 Million ≈ $56.74 Million |
€188.27 Million ≈ $220.11 Million |
-10.96pp |
| 2023-12-31 | 36.74% | €83.14 Million ≈ $97.20 Million |
€226.30 Million ≈ $264.57 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€254.36 Million ≈ $297.38 Million |
-- |
About GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more